Phathom Pharmaceuticals announces FDA approval of VOQUEZNA

Phathom Pharmaceuticals announced today the U.S. Food and Drug Administration, FDA, has approved VOQUEZNA 10 mg tablets for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease in adults. Non-Erosive GERD represents a substantial segment of the U.S. GERD population, affecting millions of individuals suffering from frequent heartburn. This is the third FDA approval for VOQUEZNA, which is also approved to treat all severities of Erosive Esophagitis, also referred to as Erosive GERD, and in combination with antibiotics for the eradication of Helicobacter pylori infection. VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment. VOQUEZNA represents the first major innovation in GERD treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S.